For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…